Fairvalue-Calculator Fairvalue-Calculator
EN DE

Genebiotech Co (086060) Fair Value & Analysis

Healthcare · KR · Market cap 34.1B KRW

Price4,365 KRW
Fair Value7,695 KRW
Upside+76.3%
Quality95/100
Evidence: High Range 5,771 KRW – 9,619 KRW

Fair value as of: Jun 25, 2026

Analysis

Genebiotech Co (086060) currently trades at 4,365 KRW, while our model-based Fair Value estimate is 7,695 KRW — implying the stock looks roughly 76.3% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

Genebiotech Co., Ltd., a specialized fermentation company, researches, develops, produces, and sells biological resources for use in animal resources, agriculture, food, medicine, etc. It offers functional feed ingredients and additives, as well as veterinary medicines. The company was founded in 1984 and is headquartered in Gongju, South Korea.

Open the full interactive analysis →

Similar stocks

ST Pharm Co (237690) -49% NatureCell Co (007390) -97% Oscotec Inc (039200) -10% DongKook Pharmaceutical Co (086450) +50% Kolon Life Science Inc (102940) -17% Komipharm International Co (041960) -94%

Frequently asked questions

Is Genebiotech Co (086060) undervalued?
As of Jun 25, 2026, our model estimates a fair value of 7,695 KRW versus a price of 4,365 KRW — about +76% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 086060?
Our 21-model fair value for Genebiotech Co is 7,695 KRW (as of Jun 25, 2026), built from audited fundamentals. The current price is 4,365 KRW.
What is the quality score of 086060?
Genebiotech Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.